Las Vegas, NV -- (SBWIRE) -- 10/05/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Celldex Therapeutics, Inc. (NASDAQ:CLDX), Sarepta Therapeutics Inc (NASDAQ:SRPT), Dendreon Corporation (NASDAQ:DNDN), Antares Pharma Inc (NASDAQ:ATRS)
Celldex Therapeutics, Inc. (NASDAQ:CLDX) managed to keep its fall at -3.58% on above-normal volume of 3.69M shares. The stock settled at $32.55 after floating in a range of $32.41 to $34.81. Its latest price has reached market capitalization of $2.64 billion. Its 52-week range has been $5.02 to $38.84. Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States.
Has CLDX Found The Bottom and Ready To Move Up? Find Out Here
Sarepta Therapeutics Inc (NASDAQ:SRPT) traded up on a volume of 3.29 million, higher than its standard daily volume. Shares have gained 5.52% to $53.48. Over the last twelve months, the stock has gained 244.37% and faced a worst price of $21.21. Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious
For How Long SRPT’s Gloss will Attract Investors? Find out via this report
Dendreon Corporation (NASDAQ:DNDN) settled -1.42% lower at $2.78 on below -normal volume of 3.27M shares during the last trading day. The stock has its 12-month high at $7.22 and 52-week low price was $2.69. It traded in a range of $2.75 to $2.81 during the last trading day. Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Its product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers.
Will DNDN Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Antares Pharma Inc (NASDAQ:ATRS) was up on high volume, trading at a volume of 3.23M versus its average daily volume of 1.21 million shares. At $4.59, the stock has attained market capitalization of 583.66 million. Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies, and topical gel-based medicines worldwide.
Will ATRS Continue To Move Higher? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)